ESR1 and cancer: Enhanced FOXA1 expression has been linked to decreased sensitivity of estrogen receptor-positive breast cancer to chemotherapy, serving as a predictor of poor prognosis in patients undergoing neoadjuvant chemotherapy for this cancer type32.